Palvella Therapeutics (PVLA) Surges On Positive Phase 3 QTORIN SELVA Data

Palvella Therapeutics Inc (NASDAQ:PVLA) shares are trading higher Tuesday morning after the company reported positive topline data from its Phase 3 SELVA study of QTORIN 3.9% rapamycin gel in microcystic lymphatic malformations. Here’s what investors need to know.

• Palvella Therapeutics stock is trading near recent highs. Where are PVLA shares going?

Phase 3 SELVA Trial Succeeds

The trial in 49 patients aged six and older met its primary endpoint on the Microcystic Lymphatic Malformation Investigator Global Assessment, with a mean improvement of over two points and gains across all key secondary measures.

Most participants were rated much or very improved, and nearly all eligible patients chose to roll into an extension study.

First Potential Therapy For Microcystic

QTORIN rapamycin targets a rare, progressive condition that currently has no U.S. Food and Drug Administration-approved treatments for 30,000 U.S. patients.

In SELVA, the topical therapy was well tolerated, with no drug-related serious adverse events and low systemic exposure reported, supporting its potential use in pediatric and adult populations.

Regulatory Filing Targeted For 2026

Based on the data, Palvella plans to submit a New Drug Application to the FDA in the second half of 2026, with potential U.S. approval in the first half of 2027.

Investors Eye Broader QTORIN Franchise

Beyond microcystic lymphatic malformations, the company is studying QTORIN rapamycin in other mTOR-driven vascular and skin disorders, which could expand its addressable market if future trials succeed. The Phase 3 win and regulatory plans are supporting sentiment in PVLA today.

Shares Show Exceptional Bullish Momentum

The stock is currently trading 35.6% above its 20-day simple moving average and 28.2% above its 100-day SMA, demonstrating strong short-term and longer-term strength.

Shares have increased 451.53% over the past 12 months and are currently positioned closer to their 52-week highs than lows, reinforcing the bullish sentiment around the stock.

The RSI is at 53.09, which is considered neutral territory, indicating that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at -1.9796, with the signal line at -3.2456, suggesting bullish momentum as the MACD is above the signal line.

The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating potential for further upward movement if positive sentiment continues.

• Key Resistance: $114.50
• Key Support: $90.00

PVLA Shares Climb Sharply Tuesday

PVLA Price Action: Palvella Therapeutics shares were up 33.23% at $118.01 at the time of publication on Tuesday. The stock is approaching its 52-week high of $114.69, according to Benzinga Pro data.

Image: Shutterstock